Hair Loss Medicine, Don't Take It, Spray It... Boryeong Launches 'Pinjuve Spray'

Spray-type finasteride hair loss medication 'Pinjuve Spray' from Boryeong [Photo by Boryeong]

Boryung announced on the 13th that it will launch Korea's first spray-form finasteride hair loss treatment, 'Finjuve Spray 2.275㎎/㎖', on the 21st. After securing the exclusive domestic distribution rights for Finjuve Spray from Almirall in January last year, Boryung obtained product approval in September of the same year and is now proceeding with the official launch.

Finjuve Spray is a hair loss treatment developed by Almirall, a global pharmaceutical company specializing in dermatological medicines. It contains finasteride, a component prescribed for androgenetic alopecia in adult men, developed in a spray form rather than oral administration. The topical treatment method sprays directly onto the scalp in the hair loss area, which lowers blood concentration compared to oral finasteride, thereby reducing side effects. Boryung explained that the treatment effect is at a level equivalent to oral finasteride. In Phase 3 clinical trials, after 24 weeks of administration, the number of hairs in the target area (TAHC) showed an effect equivalent to oral finasteride 1㎎, and the blood concentration was about 1/100th, with the incidence of adverse events after administration being lower than that of the oral finasteride group.

Finjuve Spray contains a water-soluble semi-synthetic polymer with high skin affinity, developed to allow the main ingredient finasteride to penetrate deeply into the dermis of the scalp. It is applied once daily to the hair loss area, sprayed 1 to 4 times per application, and should not exceed 4 times per day. Each spray delivers 50 μl containing Finasteride 114 μg. When spraying the drug, a cone-shaped spray-specific cone is assembled onto the bottle to efficiently apply it to the hair loss area while preventing dispersion to the outside.

According to the pharmaceutical market research firm Ubist, last year, among the total domestic market of 134.8 billion KRW for oral male hair loss treatments, prescriptions for oral finasteride accounted for 112.7 billion KRW, representing 83.6%, establishing it as a popular option for hair loss treatment. Boryung expects Finjuve Spray to establish itself as a new treatment option in the hair loss market based on its lower incidence of adverse events compared to oral formulations and equivalent treatment efficacy.

Sung Baek-min, Head of Rx Marketing at Boryung, stated, “Finjuve Spray has an effect equivalent to oral finasteride 1㎎, which has the largest prescription amount in the domestic male hair loss treatment market, and through formulation improvement, it reduces blood concentration to about 1/100th compared to oral drugs, improving side effects. It will be an innovative choice for male patients suffering from androgenetic alopecia.”

Detailed information about Finjuve Spray (usage methods and precautions, etc.) can be found through Boryung’s physician-exclusive information portal ‘BR!dge’.